Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares of […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year price target among […]
/PRNewswire/ DelveInsight s Stuttering Market Insights report includes a comprehensive understanding of current treatment practices, stuttering emerging.
The anticipated introduction of new therapeutic options could lead to an expansion of the market for stuttering treatment during the forecast period. This growth may be fueled by factors such